Joint Pain Injections Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Joint Pain Injections Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Joint Pain Injections Market

The joint pain injections market size was valued at USD 5.25 billion in 2023, and the market is now projected to grow from USD 5.77 billion in 2024 to USD 12.71 billion by 2032, exhibiting a CAGR of 10.4% during the forecast period of 2024-2032.

The market went down during the COVID-19 pandemic because of the fewer visits for patient treatment, hence the overall demand for joint pain injections went down. Nevertheless, the growing number of musculoskeletal conditions among the general population and the intensive activity of the key market players on the development and introduction of new products are expected to be the driving force of the joint pain injections market growth during the projected period

The incidence of sports injuries, tending to be ligament/ muscle injuries across the world, has become more prevalent, resulting in the elevated volume of the patient population which is suffering from these pains and other bone disorders. With the increasing number of patients, so do the needs for pain management such as joint pain injections therapy, and others. The parallel development of traumas, recourse to the government and others to spread the word about musculoskeletal conditions, and the wide treatment choices at hand are projected to be the growth drivers for these products. Moreover, the rising consumption on a per capita basis by the countries already developed and also the launch of new products being made by the market players will egg on the demand for intra-articular injection in the global market. As a whole, these items will impact the joint pain injections market share.

Innovative drugs invented and designed by the pharmaceutical industry are now able to fight osteoarthritis to treat some musculoskeletal conditions. The increasing knowledge of patients concerning minimally invasive approaches for treatment and management of these diseases as well as facilitating the use of these approaches, including such benefits as rapid adsorption of the drug, the extended relief period for patients, reduced pain and others leads to higher preference for such procedures among the patient population.

Comprehensive Analysis of Joint Pain Injections Market

Due to product diversification, the joint pain injections industry and the healthcare space are unabatedly increasing in size. With the flourishing of this market high-level regional evaluations that are multi-dimensioned can be made which consider the essential supply and demand determinants of the agricultural sector. Divisions are created strictly by product, joint type, and distribution channelTypes for injections are corticosteroids, hyaluronic acid, and platelet-rich plasma and they are the most common. The knee, hips, hand & wrist, are the main joints for the market are included. Distribution channels are classified as hospital pharmacies, retail pharmacies, and online pharmacies.

North America occupied the first position of the world joint pain injections market size in 2023 with a value of USD 2. 37 billion. The predominant international locations in North America, the U.S., and Canada, are involved in the growing trend of osteoarthritis among patient populations mainly due to the increasing use of intra-articular injections as remedy options.

The pinnacle gamers inside the marketplace play a critical function in the healthcare sector assuring commercial prospectus boom and setting market standards. These gamers consist of, SEIKAGAKU COMPANY (Japan), Bioventus (US), Anika Therapeutics, Inc. (US), Zimmer Biomet (US), Sanofi (France), Pacira BioSciences, Inc. (US),Teva Drug Industries Ltd. (Israel),Ferring B.V. (Switzerland), Dr. Redddys & Laboratories Ltd. (India). Not only do these market players offer a level-planning competitive landscape, but they are also competitive on the line.

In December 2023, Bioventus achieved a nationwide contract with Aetna, under the Medicare Advantage plans, where the over 3 million Aetna Medicare Advantage plan members, will now have the accessibility to DUROLANE, the HA-based treatment to ease the symptoms of both knees caused by an OA.

Segmentation Table

Global Joint Pain Injections Market Scope

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 10.4% from 2024 to 2032

Unit Value (USD billion)

Segmentation By Product, By Joint Type, By Distribution Channel, By Geography

By Product Corticosteroid Injections

Hyaluronic Acid Injections

Platelet Rich Plasma Injections

Others

By Joint Type Knee

Hip

Hand & Wrist

Others

By Distribution Channel Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography

North America (By Product, Joint Type, Distribution Channel, and Country)

- U.S.

- Canada

Europe (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)

- Germany

- U.K.

- France

- Italy

- Spain

- Scandinavia

- Rest of Europe

Asia Pacific (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)

- China

- Japan

- India

- Australia

- Southeast Asia

- Rest of the Asia Pacific

Latin America (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)

- Brazil

- Mexico

- Rest of Latin America

Middle East & Africa (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)

- GCC

- South Africa

- Rest of the Middle East & Africa


Please Note: It will take 2-3 business days to complete the report upon order confirmation.